argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025

Core Points - argenx SE is holding an Extraordinary General Meeting of shareholders on November 18, 2025, at 14:00 CET in Amsterdam, Netherlands [1] - The meeting will include the proposal for the adoption of a revised remuneration policy [3] Company Overview - argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [4] - The company collaborates with leading academic researchers through its Immunology Innovation Program to develop novel antibody-based medicines [4] - argenx has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential in various serious autoimmune diseases [4]